A Multicenter Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota (CP101) in Subjects with Recurrence of Clostridium Difficile Infection

The objectives of this Phase 2 study are to evaluate the safety and tolerability of CP101 treatment compared to placebo in adults with previously treated, recurrent Clostridium difficile infection, and to evaluate the efficacy of CP101 treatment relative to placebo in adults with previously treated, recurrent Clostridium difficile infection.

0